Filing Flows › Cirtran (CIRX) › Q1 2026 › vs Q1 2025
Cirtran (CIRX) Q1 2026 vs Q1 2025 (year over year)
Cirtran's revenue rose $701K (+152%) from $461K in Q1 2025 to $1.2M in Q1 2026. The biggest changes: Tobacco Line +$692K (+162%); All Other Product Line +$8K (+26%). Gross margin 39.9% against 58.7% (-18.8 pts).
Cirtran, Q1 2026: revenue $1.2M (+152% year over year), operating margin 3.1%, net earnings $2.2M, operating cash flow −$59K. The chart draws each line against Q1 2025, the increases inside each band.
Margins
| Q1 2026 | Q1 2025 | Change | |
|---|---|---|---|
| Gross margin | 39.9% | 58.7% | -18.8 pts |
| Operating margin | 3.1% | -9.4% | +12.5 pts |
| Net margin | 191.2% | -33.7% | +224.9 pts |
Every line
| Line | Q1 2026 | Q1 2025 | Change | % |
|---|---|---|---|---|
| Tobacco Line | $1.1M | $429K | $692K | +162% |
| All Other Product Line | $41K | $32K | $8K | +26% |
| Revenue | $1.2M | $461K | $701K | +152% |
| Gross profit | $463K | $270K | $193K | +71% |
| Cost of revenue | $698K | $191K | $507K | +266% |
| Other income, net | $2.2M | −$103K | $2.3M | — |
| Operating profit | $36K | −$43K | $79K | — |
| Operating expenses | $427K | $314K | $114K | +36% |
| Pre-tax earnings | $2.2M | −$146K | $2.4M | — |
| SG&A | $297K | $185K | $113K | +61% |
| Other operating costs | $130K | $129K | $1K | +0.9% |
| Net earnings | $2.2M | −$155K | $2.4M | — |
| Operating cash sources | $2.3M | $313K | $2.0M | +628% |
| Depreciation | $476 | $1K | −$25 | -5% |
| Cash used in operations | $59K | $468K | −$409K | -87% |
| Working capital & other | $2.3M | $313K | $2.0M | +628% |
Questions
How much did Cirtran's revenue grow year over year in Q1 2026?
Cirtran's revenue rose $701K (+152%) from $461K in Q1 2025 to $1.2M in Q1 2026.
What drove Cirtran's revenue change in Q1 2026?
Tobacco Line +$692K (+162%); All Other Product Line +$8K (+26%).